AGC Biologics announced multipurpose facility in its Copenhagen, Denmark site to increase its capacity and space to accommodate new and existing clients’ needs. The new facility will include a manufacturing building comprised of four levels holding approximately 8,000 square meters distributed across manufacturing, quality control laboratories, technical and warehouse areas. In addition, there will be an office building, and a visitors center. This will generate around 250-300 new workplaces in Denmark. The production will be focused genetically modified organisms, biosafety level 1, manufactured with single-use technology in clean rooms.
This expansion allows AGC Biologics to further strengthen its market position in the biopharmaceuticals CDMO market. This investment will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen. It represents the commitment and the dedication that AGC Biologics has in providing high-level technological solutions to its current and future customers.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.